Document is current
Any future updates will be listed below
-
Authors
Pandey, Krupa Shah
Giles, Kathryn
Balashov, Konstantin
Macdonell, Richard https://orcid.org/0000-0001-6604-3968
Windsheimer, Jörg
Martinez, Mikel
Božin, Ivan https://orcid.org/0009-0008-2205-4233
Raynaud, Stephanie
Scaramozza, Matthew https://orcid.org/0000-0003-3738-459X
Mokliatchouk, Oksana
Sun, Zhaonan https://orcid.org/0000-0001-5333-4387
Belviso, Nicholas
Sato, Yayoi https://orcid.org/0009-0005-8747-2450
Lin, Xiaochen
Okai, Annette
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02047097 at ClinicalTrials.govDocuments that mention this clinical trial
099 Safety and effectiveness of dimethyl fumarate in multiple sclerosis patients treated over 5 years
https://doi.org/10.1136/jnnp-2022-abn.424
Real-World Safety and Effectiveness After 5 Years of Dimethyl Fumarate Treatment in Black and Hispanic Patients with Multiple Sclerosis in ESTEEM
https://doi.org/10.1007/s40120-023-00517-1
Long-Term Safety and Effectiveness of Dimethyl Fumarate in Patients with Multiple Sclerosis Treated in Routine Medical Practice: Final Analysis of the ESTEEM Study
https://doi.org/10.1007/s40120-024-00680-z
044 Safety and efficacy of dimethyl fumarate in ESTEEM UK cohort
https://doi.org/10.1136/jnnp-2022-abn.83
-
Funding
Funding for this research was provided by:
Biogen
- License Information
-
More Information
Article History
Received: 12 August 2024
Accepted: 22 October 2024
First Online: 14 December 2024
Declarations
:
: Krupa Shah Pandey: consulting fees from Bristol Myers Squibb; fees for non-CME services and/or speaker bureaus from Alexion, Biogen, Bristol Myers Squibb, Genentech, and Sanofi; research support from Genentech. Kathryn Giles: consulting fees from Biogen, EMD Serono, and Genzyme. Konstantin Balashov: consulting fees from Genentech; research support from Biogen. Richard Macdonell: consulting fees and research support from Biogen, Celgene, Genentech, Genzyme, and Teva; speaker bureau for Biogen, Celgene, Genentech, Genzyme, and Teva. Jörg Windsheimer: consulting fees from Genzyme, Merck, Novartis, Roche, and Teva. Mikel Martinez: consulting fees from Genzyme, Novartis, and Pfizer. Ivan Božin, Matthew Scaramozza, Oksana Mokliatchouk, Zhaonan Sun, Nicholas Belviso, Yayoi Sato, Xiaochen Lin: employees of Biogen and may hold stock in the company. Stephanie Raynaud: employee of and held stock/stock options in Biogen at the time this work was conducted. Annette Okai: consulting fees from Biogen, Bristol Myers Squibb, EMD Serono, Novartis, Roche-Genentech, and Sanofi-Genzyme; research support from Biogen, Bristol Myers Squibb, Roche-Genentech, and Sanofi Genzyme; speaker bureau for Biogen, Bristol Myers Squibb, EMD Serono, Roche-Genentech, and Sanofi-Genzyme.
: The study was conducted in accordance with protocol, the International Council for Harmonization Guideline E6, all applicable local regulatory requirements, and ethical principles based on the Declaration of Helsinki.
